These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 7964949

  • 1. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer.
    Murray N, Coppin C, Coldman A, Pater J, Rapp E.
    J Clin Oncol; 1994 Nov; 12(11):2333-9. PubMed ID: 7964949
    [Abstract] [Full Text] [Related]

  • 2. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
    Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM.
    J Clin Oncol; 1988 Apr; 6(4):633-41. PubMed ID: 2833577
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
    Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M.
    J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
    [Abstract] [Full Text] [Related]

  • 4. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
    Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R, Greco FA.
    J Clin Oncol; 1990 May; 8(5):886-91. PubMed ID: 2159054
    [Abstract] [Full Text] [Related]

  • 5. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
    Le Chevalier T, Brisgand D, Pujol JL, Douillard JY, Monnier A, Rivière A, Chomy P, Le Groumellec A, Ruffie P, Gottfried M, Gaspard MH, Chevreau C, Alberola V, Cigolari S, Besson F, Martinez A, Besenval M, Berthaud P, Tursz T.
    Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
    [Abstract] [Full Text] [Related]

  • 6. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S.
    Anticancer Res; 2000 May; 20(3B):1985-90. PubMed ID: 10928138
    [Abstract] [Full Text] [Related]

  • 7. Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?
    Masutani M, Tsujino I, Fujie T, Yamaguchi M, Miyagi K, Yano T, Takahashi N, Koya Y, Horie T.
    Oncol Rep; 1999 May; 6(5):1045-50. PubMed ID: 10425301
    [Abstract] [Full Text] [Related]

  • 8. A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
    Levitan N, Dowlati A, Craffey M, Tahsildar H, MacKay W, McKenney J, Remick SC.
    Lung Cancer; 1998 Dec; 22(3):227-34. PubMed ID: 10048475
    [Abstract] [Full Text] [Related]

  • 9. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors.
    Kodani T, Ueoka H, Kiura K, Tabata M, Takigawa N, Segawa Y, Moritaka T, Hiraki S, Harada M, Tanimoto M.
    Lung Cancer; 2002 Jun; 36(3):313-9. PubMed ID: 12009244
    [Abstract] [Full Text] [Related]

  • 10. Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study.
    Makrantonakis P, Ziotopoulos P, Agelidou A, Polyzos A, Ziras A, Chandrinos V, Vossos A, Kalykaki A, Androulakis N, Geroyianni A, Georgoulias V, Lung Cancer Committee of the Hellenic Oncology Research Group.
    Lung Cancer; 2006 Jul; 53(1):85-90. PubMed ID: 16720058
    [Abstract] [Full Text] [Related]

  • 11. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA, SQUIRE Investigators.
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [Abstract] [Full Text] [Related]

  • 12. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
    Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S.
    J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
    [Abstract] [Full Text] [Related]

  • 13. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N.
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [Abstract] [Full Text] [Related]

  • 14. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D, Golubicic I, Gavrilovic D, Kezic I, Jelic S.
    J BUON; 2009 Jan; 14(2):203-9. PubMed ID: 19650167
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L, LeChevalier T, Gottfried M, Adams D, Ruffie P, LeCesne A, Tete L, Pellae-Cosset B.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [Abstract] [Full Text] [Related]

  • 16. [Cisplatin, doxorubicin and vindesine in the treatment of advanced non-small cell lung cancer].
    Akiyama J, Sato A, Honda K, Chida K, Watanabe T, Okano H, Okano A, Taniguchi M, Genma H, Aoki H.
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):419-24. PubMed ID: 1848420
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. An LCSG Trial.
    Feld R, Rubinstein L, Thomas PA.
    Chest; 1994 Dec; 106(6 Suppl):307S-309S. PubMed ID: 7988250
    [Abstract] [Full Text] [Related]

  • 18. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ, Fournel P, Bohas CH, Fortune IC, Chatte G.
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [Abstract] [Full Text] [Related]

  • 19. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
    Takifuji N, Fukuoka M, Negoro S, Takada M, Kusunoki Y, Matsui K, Masuda N, Ryu S, Sakai N, Kubota K.
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):429-34. PubMed ID: 2157364
    [Abstract] [Full Text] [Related]

  • 20. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M, Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan).
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.